Risk Management in the Treatment of Malignant Gliomas with BCNU Wafer Implants

Abstract

Implantation of BCNU wafers (Gliadel^®) into the resection cavity has demonstrated a survival benefit for patients with newly diagnosed malignant gliomas. The follow-up of two phase III trails has further shown that the number of long-term survivors was significantly increased by BCNU wafer treatment. BCNU wafer implantation may be integrated into current multimodal first line strategies. In the setting of recurrent disease BCNU wafer implantation has also shown a survival benefit and now extends the treatment options in a patient population that typically has undergone extensive pretreatment. An analysis of the literature has helped to clearly identify the risks associated with topic BCNU treatment. Here we summarize the incidence and time course of adverse events associated with local chemotherapy and propose solutions. The growing body of experience with BCNU wafer implantation may serve as a basis to develop adequate risk management strategies with regard to patient selection, surgical techniques, and follow-up schedules.

Key words

glioma - glioblastoma - local chemotherapy - BCNU wafer - carmustine

References

• 1 Clinical Practice Guidelines in Oncology .Central Nervous System Cancers, edition v1.2008. National Comprehensive Cancer Network. 2008 Available at http://http://www.nccn.org/professionals/physician_gls/pdf/cns.pdf
• 2 Final appraisal determination– carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma .National Institute for Health and Clinical Excellence. 2007 Available at. http://http://www.nice.org.uk/nicemedia/pdf/glioma_carmustine_fad.pdf
• 3 Gliadel ® Wafer [prescribing information] . MGI PHARMA, Bloomington, MN, USA 2006; 
• 4 Gliadel ® Wafer [summary of product characteristics] . West Sussex, UK 2006; 
• 5 MGI PHARMA .Gliadel Wafer: Heath Care Professionals. Available at. http://http://www.gliadel.com/hcp/default.aspx [Last accessed 21 February 2008]
• 6 MGI PHARMA .How to Use GLIADEL^® Wafer. 2007 Available at. http://http://www.gliadel.com/hcp/about/how.aspx [Last accessed 6 May 2008].
• 7 Barker 2nd FG,. Efficacy of prophylactic antibiotics against meningitis after craniotomy: a meta-analysis.  Neurosurgery. 2007;  60 887-894 discussion 887–894
• 8 Bertin ML MA, Barnett G, Gordon S. Risk factors for surgical site infection after 1,3- bis (2-chlorethyl)-1-nitrosurea (BCNU) Gliadel wafer implantation for glioblastoma.  Infect Control Hosp Epidemiol. 2000;  21 (Abstract) 144
• 9 Brem H, Piantadosi S, Burger PC. et al . Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-Brain Tumor Treatment Group.  Lancet. 1995;  345 1008-1012
• 10 Brem H, Tamargo RJ, Olivi A. et al . Biodegradable polymers for controlled delivery of chemotherapy with and without radiation therapy in the monkey brain.  J Neurosurg. 1994;  80 283-290
• 11 Darakchiev BJ, Albright RE, Breneman JC. et al . Safety and efficacy of permanent iodine-125 seed implants and carmustine wafers in patients with recurrent glioblastoma multiforme.  J Neurosurg. 2008;  108 236-242
• 12 Engelhard HH. The role of interstitial BCNU chemotherapy in the treatment of malignant glioma.  Surg Neurol. 2000;  53 458-464
• 13 Erickson LC, Laurent G, Sharkey NA. et al . DNA cross-linking and monoadduct repair in nitrosourea-treated human tumour cells.  Nature. 1980;  288 727-729
• 14 Esteller M, Garcia-Foncillas J, Andion E. et al . Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents.  N Engl J Med. 2000;  343 1350-1354
• 15 Fung LK, Ewend MG, Sills A. et al . Pharmacokinetics of interstitial delivery of carmustine, 4-hydroperoxycyclophosphamide, and paclitaxel from a biodegradable polymer implant in the monkey brain.  Cancer Res. 1998;  58 672-684
• 16 Gallego JM, Barcia JA, Barcia-Marino C. Fatal outcome related to carmustine implants in glioblastoma multiforme.  Acta Neurochir (Wien). 2007;  149 261-265 discussion 265
• 17 Gibson NW, Hartley J, La France RJ. et al . Differential cytotoxicity and DNA-damaging effects produced in human cells of the Mer+ and Mer- phenotypes by a series of alkyltriazenylimidazoles.  Carcinogenesis. 1986;  7 259-265
• 18 Giese A, Kucinski T, Knopp U. et al . Pattern of recurrence following local chemotherapy with biodegradable carmustine (BCNU) implants in patients with glioblastoma.  J Neurooncol. 2004;  66 351-360
• 19 Golden GA, Meldorf M, Group PS. Number of wafers used in a cohort of 322 patients implanted with Gliadel wafer.  Neuro-Oncol. 2004;  6 (Abstract) 375
• 20 Gururangan S, Cokgor L, Rich JN. et al . Phase I study of Gliadel wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas.  Neuro-Oncol. 2001;  3 246-250
• 21 Hammond LA, Eckardt JR, Kuhn JG. et al . A randomized phase I and pharmacological trial of sequences of 1,3-bis(2-chloroethyl)-1-nitrosourea and temozolomide in patients with advanced solid neoplasms.  Clin Cancer Res. 2004;  10 1645-1656
• 22 Hammoud DA, Belden CJ, Ho AC. et al . The surgical bed after BCNU polymer wafer placement for recurrent glioma: serial assessment on CT and MR imaging.  AJR Am J Roentgenol. 2003;  180 1469-1475
• 23 Hughes MA, Parisi M, Grossman S. et al . Primary brain tumors treated with steroids and radiotherapy: low CD4 counts and risk of infection.  Int J Radiat Oncol Biol Phys. 2005;  62 1423-1426
• 24 Jones NS, Becker DG. Advances in the management of CSF leaks.  BMJ. 2001;  322 122-123
• 25 McGirt MJ, Than KD, Weingart JD. et al . Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme.  J Neurosurg. 2009;  110 583-588
• 26 McGovern PC, Lautenbach E, Brennan PJ. et al . Risk factors for postcraniotomy surgical site infection after 1,3-bis (2-chloroethyl)-1-nitrosourea (Gliadel) wafer placement.  Clin Infect Dis. 2003;  36 759-765
• 27 Menei P, Metellus P, Loiseau H. et al .Biodegradable carmustine impregnated wafers (Gliadel): the French experience. Neuro-Oncol, (EANO); 2008 (Abstract): 1138.
• 28 Miliaras G, Tsitsopoulos PP, Markoula S. et al . Multifocal glioblastoma with remote cutaneous metastasis: a case report and review of the literature.  Cent Eur Neurosurg. 2009;  70 (1) 39-42
• 29 Mitchell RB, Dolan ME. Effect of temozolomide and dacarbazine on O6-alkylguanine-DNA alkyltransferase activity and sensitivity of human tumor cells and xenografts to 1,3-bis(2-chloroethyl)-1-nitrosourea.  Cancer Chemother Pharmacol. 1993;  32 59-63
• 30 Pan E, Mitchell SB, Tsai JS. A retrospective study of the safety of BCNU wafers with concurrent temozolomide and radiotherapy and adjuvant temozolomide for newly diagnosed glioblastoma patients.  J Neurooncol. 2008;  88 353-357
• 31 Plowman J, Waud WR, Koutsoukos AD. et al . Preclinical antitumor activity of temozolomide in mice: efficacy against human brain tumor xenografts and synergism with 1,3-bis(2-chloroethyl)-1-nitrosourea.  Cancer Res. 1994;  54 3793-3799
• 32 Prager JM, Grenier Y, Cozzens JW. et al . Serial CT and MR imaging of carmustine wafers.  AJNR Am J Neuroradiol. 2000;  21 119-123
• 33 Psaras T, Will BE, Schoeber W. et al . Quantitative assessment of postoperative blood collection in brain tumor surgery under valproate medication.  Zentralbl Neurochir. 2008;  69 (4) 165-169
• 34 Raizer JJ, Malkin MG, Kleber M. et al . Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy.  Neuro-Oncol. 2004;  6 247-252
• 35 Raslan A, Bhardwaj A. Medical management of cerebral edema.  Neurosurg Focus. 2007;  22 E12
• 36 Sabel M, Giese A. Safety profile of carmustine wafers in malignant glioma: a review of controlled trials and a decade of clinical experience.  Curr Med Res Opin. 2008;  24 (11): 3239-3257
• 37 Schröter S, Halatsch ME, Behnke-Mursch J. et al . Self-help activities of brain tumour patients and their relatives.  Cent Eur Neurosurg. 2009;  70 (1) 21-26
• 38 Sampath P, Brem H. Implantable slow-release chemotherapeutic polymers for the treatment of malignant brain tumors.  Cancer Control. 1998;  5 130-137
• 39 Stupp R, Mason WP, van den Bent MJ. et al . Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.  N Engl J Med. 2005;  352 987-996
• 40 Tamargo RJ, Epstein JI, Reinhard CS, Chasin M, Brem H. Brain biocompatibility of a biodegradable, controlled-release polymer in rats.  J Biomed Mater Res. 1989;  23 253-266
• 41 Valtonen S, Timonen U, Toivanen P. et al . Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: a randomized double-blind study.  Neurosurgery. 1997;  41 44-48 discussion 48–49
• 42 van Breemen MS, Wilms EB, Vecht CJ. Epilepsy in patients with brain tumours: epidemiology, mechanisms, and management.  Lancet Neurol. 2007;  6 421-430
• 43 Weber EL, Goebel EA. Cerebral edema associated with Gliadel wafers: two case studies.  Neuro-Oncol. 2005;  7 84-89
• 44 Westphal M, Hilt DC, Bortey E. et al . A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma.  Neuro-Oncol. 2003;  5 79-88

Correspondence